Ainos reports FY2023 revenue drop to $122K; net loss $13.8M

Ainos, Inc.

Revenue fell 97% to $122,112 from $3.52M in 2022, driven by COVID-19 test kit sales decline.
Gross loss of $253,733 vs positive gross profit of $1.4M a year earlier; net loss $13.77M vs $14.01M.
Cash and cash equivalents $1.89M at Dec 31, 2023, nearly flat from $1.85M at Dec 31, 2022.
R&D expenses rose to $7.32M; SG&A fell to $5.64M on lower share-based compensation.
Strategic pivot: advancing VELDONA Phase III, AI Nose VOC platform with NISD & Inabata, and pet supplement sales.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ainos, Inc. reported the year ended December 31, 2023 results: revenue US$122,112, net income US$13,770,549.

Period: the year ended December 31, 2023
Revenue: US$122,112
Net income: US$13,770,549
Result: reported results

Exact text from the filing

amount of US$3 million. These transactions provided us with additional capital as we implement our growth strategy.” Full Year 2023 Financial Results Revenues Revenues were US$122,112, compared to US$3,519,627 in the full year of 2022, reflecting a decrease in selling price and sales volume of the Company's COVID-19 Antigen Rapid Test Kits attributable to the

View on SEC.gov

Browse all earnings releases →

Ainos, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-002898

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.